Please ensure Javascript is enabled for purposes of website accessibility

Why Bed Bath & Beyond, Ra Pharmaceuticals, and Freeport-McMoRan Jumped Today

By Dan Caplinger - Oct 10, 2019 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of these stocks was pushed higher after it revealed who will next sit in the CEO's chair.

Stock market participants displayed a positive attitude on Thursday, apparently buoyed by signs that leaders of the U.S. and China will at least keep meeting in an effort to resolve their differences on trade issues. Major benchmark indexes were up by around half a percent on the day, and with earnings season just about to kick off, investors are looking forward to getting more signs about the likely direction of the U.S. economy for the rest of the year.

Some stocks experienced extremely strong gains due to company-specific good news. Bed Bath & Beyond (BBBY -3.57%), Ra Pharmaceuticals (RARX), and Freeport-McMoRan (FCX 0.10%) were among the day's top performers. Here's why their shares did so well.

Bed Bath & Beyond gets a new CEO

Shares of Bed Bath & Beyond jumped 21% after the home goods retailer announced that it had named a permanent chief executive officer: Mark Tritton, previously the chief merchandising officer for Target. Shareholders were quite happy with the move, as Target has been extremely successful in finding ways to overcome a tough environment for traditional brick-and-mortar department stores. Bed Bath & Beyond is hopeful that Tritton can work the same magic with home goods, and shareholders appear to have a lot of confidence in his ability to get the retailer moving in the right direction again.

Bed and nighttable in a room with windows and open plan, with Bed Bath & Beyond logo.

Image source: Bed Bath & Beyond.

Rah-rah for Ra

Ra Pharmaceuticals' stock doubled in value Thursday after the clinical-stage biopharmaceutical company got a buyout bid from industry peer UCB. The  Belgian company offered roughly $2.1 billion for Ra, with shareholders to receive $48 per share in cash. UCB CEO Jean-Christophe Tellier described Ra Pharma as "an excellent strategic fit" for his company that would add to its already significant product pipeline and enhance its growth prospects. Ra CEO Doug Treco also pointed to the value of his company's ExtremeDiversity technology platform, which should help the combined company move forward in the development of more innovative products. The big premium came as a surprise to investors, but Ra shareholders couldn't be happier with the deal.

Freeport gets an upgrade

Finally, shares of Freeport-McMoRan moved higher by 5%. The copper and gold mining company got favorable comments from analysts at UBS, including an upgrade for the stock from neutral to buy. UBS believes that investors have focused too much on temporarily low copper prices in bidding down the value of Freeport's shares, while ignoring the longer-term factors likely to drive the mining company's success. It's true that the price of copper tends to track economic growth closely, and prospects for the global economy are uncertain. Yet with gold having come back into favor  among investors, Freeport might well be in the right place at the right time.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Freeport-McMoRan Inc. Stock Quote
Freeport-McMoRan Inc.
FCX
$31.02 (0.10%) $0.03
Bed Bath & Beyond Inc. Stock Quote
Bed Bath & Beyond Inc.
BBBY
$6.75 (-3.57%) $0.25
Ra Pharmaceuticals, Inc. Stock Quote
Ra Pharmaceuticals, Inc.
RARX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.